Piotr Jedryszek
| Piotr Jedryszek | |
| Occupation | CTO and co-founder of Evolvere BioSciences |
|---|---|
| Known for | Co-founding Evolvere BioSciences |
Piotr Jedryszek is a Polish-born biotechnology entrepreneur and computational biologist. He is the co-founder and chief technology officer (CTO) of Evolvere BioSciences, a biotech company developing next-generation antibiotics designed to outpace bacterial evolution. The company participated in Y Combinator's Summer 2024 batch.[1]
Career
Jedryszek studied at the University of Oxford, where he met his Evolvere BioSciences co-founders, including Adam Winnifrith and Weronika Slesak. The founding team comprises biochemists and evolutionary biologists.[1] At Evolvere BioSciences, Jedryszek serves as CTO, where he plays a central role in integrating data science and biotechnology to advance the company's drug discovery platform.
Evolvere BioSciences develops computational models to design antibiotics that can overcome antibiotic resistance, a growing global health crisis that already kills more people annually than malaria and AIDS. The company's approach uses co-evolutionary protein-protein interaction datasets combined with artificial intelligence to forecast bacterial mutations and create antibiotics that remain effective against future resistant strains. The platform aims to precisely target pathogenic bacteria while leaving beneficial microbes and human cells unharmed. By anticipating how bacteria will evolve resistance, Evolvere BioSciences seeks to extend the useful lifespan of new antibiotics and reduce the frequency with which new drugs must be developed.[1]
The company operates at the intersection of several fields, including AI-powered drug discovery, synthetic biology, and therapeutics. It is based in Oxford, United Kingdom.[2]
In 2023, Jedryszek and Slesak were recognised as laureates of Forbes Poland's "25 before 25" list, which highlighted the pair's work on their antibiotic development platform while studying at Oxford. In April 2023, Jedryszek contributed to a technical blog post published by Amazon Web Services describing how Evolvere BioSciences performs macromolecule design using AWS cloud infrastructure. The company was also identified as one of the European startups selected for Y Combinator's S24 batch.
References
- ↑ 1.0 1.1 1.2 "Evolvere BioSciences". 'Y Combinator}'. Retrieved 2026-03-18.
- ↑ "Evolvere BioSciences". 'Evolvere BioSciences}'. Retrieved 2026-03-18.